Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=-title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-title" }, "data": [ { "type": "Grant", "id": "5726", "attributes": { "award_id": "3U24TR002306-05S1", "title": "A National Center for Digital Health Informatics Innovation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 19749, "first_name": "LEONIE", "last_name": "Misquitta", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-25", "end_date": "2023-06-30", "award_amount": 96811, "principal_investigator": { "id": 19750, "first_name": "CHRISTOPHER G", "last_name": "CHUTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19751, "first_name": "David A.", "last_name": "Eichmann", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 19752, "first_name": "MELISSA A", "last_name": "HAENDEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 19753, "first_name": "Adam Benjamin", "last_name": "Wilcox", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Local solutions rarely scale to multi-institutional settings, and don’t realize the vision of CTSAs catalyzing data- driven translational research. Data, Software, and People are Largely Decentralized and Unconnected in CTSA. CTSAs hold a wealth of data that is neither accessible nor interoperable; this hinders opportunities to innovate algorithms and tools. Tools in turn, suffer from myopic focus or blind duplication. It is extremely difficult to identify expert partners whether for functionally validating a candidate variant for a rare disease, finding clinical cohorts, or navigating the IP odyssey of starting a company. There are the challenges in building a truly learning health system where high quality clinical and research data can effectively and efficiently be reused in clinical care. The CD2H has developed the National COVID Cohort Collaborative (N3C) with COVID data from clinical institutions across the country. This publicly available data resource includes data on adults and pediatrics and can address the questions related to vaccine effectiveness, treatments and predictions of severity of illness. The Pediatric COVID-19 DREAM Challenge will ask community participants to predict severity status in children, using the National COVID Cohort Collaborative (N3C) Electronic Health Record (EHR) data. The desired outcome for this challenge is to produce trained and validated pediatric COVID-19 severity prediction models that can be implemented into a clinical workflow in an EHR to help facilitate appropriate treatment.", "keywords": [ "Address", "Adult", "Algorithmic Software", "Algorithms", "Architecture", "Area", "Benchmarking", "COVID-19", "COVID-19 severity", "Child", "Childhood", "Clinical", "Clinical Data", "Clinical Research", "Collaborations", "Common Data Element", "Communities", "Community of Practice", "Computer software", "Country", "Cultural Evolution", "Data", "Data Analyses", "Data Set", "Decentralization", "Development", "Discipline", "Ecosystem", "Electronic Health Record", "FAIR principles", "Fast Healthcare Interoperability Resources", "Foundations", "Goals", "Gold", "Health", "Health system", "Individual", "Informatics", "Information Resources", "Information Technology", "Infrastructure", "Institution", "Knowledge", "Learning", "Licensing", "Longevity", "Metadata", "Methodology", "Methods", "Modeling", "Morphologic artifacts", "Outcome", "Participant", "Patients", "Pediatrics", "Prediction of Response to Therapy", "Process", "Public Health Informatics", "Quality Control", "Rare Diseases", "Reporting", "Research", "Scanning", "Science", "Severities", "Severity of illness", "Software Engineering", "Software Tools", "Synapses", "System", "Technology", "Training", "Translational Research", "United States National Institutes of Health", "Update", "Variant", "Vision", "Work", "base", "blind", "clinical care", "cloud based", "cohort", "collaborative approach", "collaborative environment", "coronavirus disease", "data ecosystem", "data harmonization", "data modeling", "data quality", "data resource", "data sharing", "data standards", "data translator", "design", "digital health", "experience", "health care quality", "implementation process", "improved", "innovation", "interoperability", "invention", "open data", "open source", "predictive modeling", "quality assurance", "software development", "success", "support network", "tool", "vaccine effectiveness" ], "approved": true } }, { "type": "Grant", "id": "7363", "attributes": { "award_id": "3DP1AI150593-02S1", "title": "A nanobody-based vaccine strategy to combat CoVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6300, "first_name": "Stacy E.", "last_name": "Ferguson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-01", "end_date": "2021-07-31", "award_amount": 442500, "principal_investigator": { "id": 20554, "first_name": "Hidde L", "last_name": "Ploegh", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 798, "ror": "https://ror.org/00dvg7y05", "name": "Boston Children's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 798, "ror": "https://ror.org/00dvg7y05", "name": "Boston Children's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The development of a vaccine that protects against SARS-CoV-2, the coronavirus responsible for the current pandemic (COVID-19), is urgently needed. We have developed camelid-derived antibody fragments – nanobodies – that target surface proteins on mouse and human antigen presenting cells. These targets include class II MHC products and the integrin alpha M (CD11b). By attaching to these nanobodies various antigens in the form of proteins or peptides, we can elicit stronger B and T cell responses against the attached payloads when compared to the corresponding ‘free’ antigens. In particular, adducts composed of the anti-CD11b nanobody with peptides of viral origin induced a protective cytotoxic CD8 T cell response in a human papillomavirus model and inspire confidence that a similar outcome may be accomplished for SARS-CoV-2. We propose to apply these strategies to generate strong adaptive immune responses against SARS-CoV-2 antigens. The anti-mouse and anti-human class II MHC-specific nanobodies recognize all allotypes and will be used to target antigens to mouse and human class II MHC products in normal and HLA-DR4 transgenic mice. CD4 T cell and antibody responses will be analyzed in these studies. Adducts composed of the CD11b nanobody and COVID-19 antigenic peptides will be used to elicit CD8 T cell responses in normal and HLA-A2 transgenic mice. For the most immunogenic SARS-CoV-2 antigens, we shall identify the minimal peptides recognized for possible inclusion in future vaccine preparations.", "keywords": [ "2019-nCoV", "Antibodies", "Antibody Formation", "Antibody Response", "Antibody titer measurement", "Antigen Targeting", "Antigen-Presenting Cells", "Antigens", "B-Lymphocytes", "CD11b Antigens", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "COVID-19", "Chloroquine", "Complement", "Coronavirus", "Disease Outbreaks", "Ebola", "Elements", "Epitopes", "Formulation", "Future", "Generations", "Genetic", "Genome", "HIV", "HLA-A2 Antigen", "HLA-DR4 Antigen", "Human", "Human Papillomavirus", "Human papillomavirus 16", "ITGAM gene", "Immune response", "Immunize", "Immunoglobulin Fragments", "Immunoglobulin Variable Region", "MHC Class II Genes", "Membrane Proteins", "Modeling", "Modification", "Monitor", "Mus", "N-terminal", "Oncogenes", "Open Reading Frames", "Outcome", "Passive Immunization", "Pathology", "Peptides", "Preparation", "Prophylactic treatment", "Proteins", "Site", "Structure", "T cell response", "T-Lymphocyte", "T-Lymphocyte Epitopes", "Techniques", "Therapeutic", "Transgenic Mice", "Vaccines", "Validation", "Viral", "Virus", "Visual", "adaptive immune response", "adduct", "base", "cell type", "combat", "cytotoxic CD8 T cells", "immunogenic", "immunogenicity", "in vivo", "innovation", "nanobodies", "pandemic disease", "pathogen", "prediction algorithm", "prophylactic", "remdesivir", "response", "small molecule", "sortase", "tumor", "vaccination strategy", "vaccine development", "vector" ], "approved": true } }, { "type": "Grant", "id": "14891", "attributes": { "award_id": "1R01HD113529-01", "title": "A Multisite RCT of a Daily Living Skills Intervention for Autistic Adolescents Prior to the Transition to Adulthood", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 9289, "first_name": "Alice S", "last_name": "Kau", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-19", "end_date": "2029-03-31", "award_amount": 690880, "principal_investigator": { "id": 31582, "first_name": "Amie Marie", "last_name": "Duncan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 897, "ror": "", "name": "CINCINNATI CHILDRENS HOSP MED CTR", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Daily living skills (DLS), which are the tasks (e.g., hygiene, cooking, laundry, managing money) that individuals do to take care of themselves at home, school, work, and in the community, are impaired in autistic adolescents without an intellectual disability (ID) such that their skills are 6-8 years behind same-aged peers. Age appropriate DLS have been linked to achieving better adult outcomes in employment, college, independent living, and overall quality of life. In the recent Lancet Commission on the future of care and clinical treatment in ASD there was a call to action to address DLS in adolescence as a potential intervention target to increase the likelihood of attaining positive adult outcomes. However, until our team began developing and evaluating the Surviving and Thriving in the Real World (STRW) intervention, there were no known comprehensive, evidence-based DLS interventions for autistic adolescents at this critical developmental period. In two recent pilot randomized clinical trials (RCTs), STRW demonstrated statistically significant and clinically meaningful gains in DLS (i.e., gains of 2-4 years of DLS over the course of a 14-week intervention) compared to a control condition (i.e., PEERS social skills intervention). In our two pilot RCTs, STRW was converted to telehealth due to COVID-19. There were equal DLS gains between in-person STRW and STRW-telehealth (STRW-T) and there were numerous benefits to telehealth delivery. The next step in this line of work is to assess the efficacy of STRW-T in a fully powered Phase 3 RCT compared to an attention control condition (PEERS-telehealth; PEERS-T) and examine the impact of improved DLS on early adult outcomes by following adolescents 6-months after high school graduation. We will enroll 192 autistic teens without ID in the 11th/12th grades and randomize them to receive STRW-T (n = 96) or PEERS-T (n = 96). Caregivers and adolescent participants will complete a comprehensive multi-method DLS battery (i.e., interview, survey, daily phone diaries, goal attainment scaling) at baseline, post-treatment, and 6-month follow- up. Young adult outcomes in work, college, and quality of life will be assessed 6-months post-high school graduation for all participants. The current proposal has the following aims: (1) examine the efficacy of STRW- T on DLS compared to PEERS-T; (2) evaluate whether the improvement in DLS outcomes by STRW-T are sustained at 6-month follow-up; (3) examine the effects of STRW-T intervention on outcomes in college, work, and QoL after high school graduation compared to PEERS. We will also explore the mediating role of improved DLS on young adult outcomes. If the aims of the proposed study are achieved, STRW-T would fill the gap in the current evidence base for treating DLS in autistic adolescents and would be the first study to examine whether a DLS intervention impacts work, college, and QoL outcomes after graduation from high school. Our long term goal is to narrow the gap between age and DLS, and also fill the existing treatment gap by disseminating and implementing this intervention into routine clinical practice for autistic teens.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7923", "attributes": { "award_id": "1R01NR019831-01A1", "title": "A Multisite Randomized Controlled Trial of EMPOWER for Family Surrogates of Critically Ill Patients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 6036, "first_name": "Karen", "last_name": "Kehl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2026-01-31", "award_amount": 843931, "principal_investigator": { "id": 23783, "first_name": "Wendy G.", "last_name": "Lichtenthal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23784, "first_name": "HOLLY GWEN", "last_name": "PRIGERSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Intensive Care Units (ICUs) are stressful places fraught with grief and potentially traumatic exposures for those witnessing a critically ill family member in pain, struggling to breathe, maintain consciousness, and stay alive. Compounding their distress, family caregivers are often thrust into the position of patient “surrogate,” needing to make life-and-death decisions on the patient's behalf. We have shown that end-of-life (EoL) decision-making is compromised by elevated symptoms of distressing and disabling grief, resulting in family surrogates making suboptimal EoL choices that often prolong patient suffering, further exacerbating surrogates' grief, trauma, and regrets. The coronavirus (COVID-19) pandemic has made this bad situation worse, particularly among Black, Indigenous, and People of Color (BIPOC). Prior efforts to address the plight of these family surrogates have proved disappointing, with some significantly worsening surrogates' psychological trauma. Yet these were not psychological interventions, much less ones using psychological techniques with proven efficacy. To address these shortcomings, we developed a brief, flexibly administered intervention applying empirically supported cognitive-behavioral and acceptance-based techniques. In an R21 pilot, this intervention, EMPOWER (Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience), dramatically reduced experiential avoidance, grief, and traumatic stress, and was associated with higher rates of advance care planning, including among BIPOC. The proposed multisite, mixed-methods trial will randomize 172 family surrogates to receive EMPOWER (N=86) or a standardized supportive conversation (SC; N=86) delivered via videoconferencing. Surrogate symptoms will be assessed pre-intervention, immediately post-intervention, and 3- and 12-months post-intervention. The primary aim of this study is to compare the efficacy of EMPOWER to SC. We hypothesize that, compared to SC, EMPOWER will yield significantly greater declines in H1a. surrogate grief and posttraumatic stress (primary outcomes) and H1b. experiential avoidance, depression, regrets, and increase patients' receipt of value concordant care (secondary outcomes). The secondary aim of this study is to contextualize quantitative RCT results. H2. Qualitative interviews will provide complementary data on perceived barriers to and facilitators of symptom improvement, dissemination, and implementation, as well as insights into the impact of medical mistrust, perceived discrimination and COVID-19 on outcomes. The third aim will explore experiential avoidance as a mediator of intervention effects: H3. Reductions in experien- tial avoidance will mediate reductions in grief and posttraumatic stress. This study is expected to confirm EMPOWER's efficacy and enhance understanding of ways to improve telehealth delivery to psychologically vulnerable and historically underserved surrogates. If successful, EMPOWER will address the urgent need for effective, culturally competent interventions for distressed surrogates, which may improve critically ill patients' EoL experience in the context of extreme challenges that have been exacerbated by the COVID-19 pandemic.", "keywords": [ "Address", "Advance Care Planning", "Affect", "Anger", "Behavioral", "Bereavement", "Black Indigenous People of Color", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "Caregivers", "Caring", "Cessation of life", "Cognitive", "Communication", "Conscious", "Coronavirus", "Critical Illness", "Data", "Decision Making", "Discrimination", "Disease", "Dissemination and Implementation", "Distress", "Emotional", "Equipment and supply inventories", "Family", "Family Caregiver", "Family health status", "Family member", "Feeling", "Goals", "Grief reaction", "Guilt", "Hospitals", "Indigenous", "Intensive Care Units", "Intervention", "Interview", "Left", "Life", "Life Experience", "Loneliness", "Mediating", "Mediation", "Mediator of activation protein", "Medical", "Medical center", "Memorial Sloan-Kettering Cancer Center", "Mental Depression", "Mental Health", "Methods", "Modeling", "Numbness", "Outcome", "Pain", "Palliative Care", "Parents", "Patient Care", "Patients", "Persons", "Positioning Attribute", "Post-Traumatic Stress Disorders", "Presbyterian Church", "Psychological Techniques", "Psychological adjustment", "Quality of Care", "Race", "Randomized", "Randomized Controlled Trials", "Regrets", "Reporting", "Risk", "Role", "Severities", "Site", "Social Distance", "Standardization", "Stress", "Structure", "Symptoms", "Techniques", "Thinking", "Trauma", "United States", "United States National Institutes of Health", "Videoconferencing", "base", "comparative efficacy", "contextual factors", "cultural competence", "efficacy evaluation", "end of life", "end of life care", "experience", "flexibility", "future implementation", "improved", "insight", "intervention effect", "loved ones", "meetings", "pandemic disease", "people of color", "post intervention", "post-traumatic stress", "post-traumatic symptoms", "primary outcome", "psychologic", "psychological distress", "psychological outcomes", "psychological trauma", "psychosocial", "racial disparity", "recruit", "reduce symptoms", "resilience", "secondary outcome", "stress symptom", "symptomatic improvement", "telehealth", "traumatic stress", "treatment as usual" ], "approved": true } }, { "type": "Grant", "id": "11641", "attributes": { "award_id": "5R01NR019831-02", "title": "A Multisite Randomized Controlled Trial of EMPOWER for Family Surrogates of Critically Ill Patients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 6036, "first_name": "Karen", "last_name": "Kehl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2026-01-31", "award_amount": 773616, "principal_investigator": { "id": 23783, "first_name": "Wendy G.", "last_name": "Lichtenthal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 27546, "first_name": "Holly Gwen", "last_name": "Prigerson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Intensive Care Units (ICUs) are stressful places fraught with grief and potentially traumatic exposures for those witnessing a critically ill family member in pain, struggling to breathe, maintain consciousness, and stay alive. Compounding their distress, family caregivers are often thrust into the position of patient “surrogate,” needing to make life-and-death decisions on the patient's behalf. We have shown that end-of-life (EoL) decision-making is compromised by elevated symptoms of distressing and disabling grief, resulting in family surrogates making suboptimal EoL choices that often prolong patient suffering, further exacerbating surrogates' grief, trauma, and regrets. The coronavirus (COVID-19) pandemic has made this bad situation worse, particularly among Black, Indigenous, and People of Color (BIPOC). Prior efforts to address the plight of these family surrogates have proved disappointing, with some significantly worsening surrogates' psychological trauma. Yet these were not psychological interventions, much less ones using psychological techniques with proven efficacy. To address these shortcomings, we developed a brief, flexibly administered intervention applying empirically supported cognitive-behavioral and acceptance-based techniques. In an R21 pilot, this intervention, EMPOWER (Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience), dramatically reduced experiential avoidance, grief, and traumatic stress, and was associated with higher rates of advance care planning, including among BIPOC. The proposed multisite, mixed-methods trial will randomize 172 family surrogates to receive EMPOWER (N=86) or a standardized supportive conversation (SC; N=86) delivered via videoconferencing. Surrogate symptoms will be assessed pre-intervention, immediately post-intervention, and 3- and 12-months post-intervention. The primary aim of this study is to compare the efficacy of EMPOWER to SC. We hypothesize that, compared to SC, EMPOWER will yield significantly greater declines in H1a. surrogate grief and posttraumatic stress (primary outcomes) and H1b. experiential avoidance, depression, regrets, and increase patients' receipt of value concordant care (secondary outcomes). The secondary aim of this study is to contextualize quantitative RCT results. H2. Qualitative interviews will provide complementary data on perceived barriers to and facilitators of symptom improvement, dissemination, and implementation, as well as insights into the impact of medical mistrust, perceived discrimination and COVID-19 on outcomes. The third aim will explore experiential avoidance as a mediator of intervention effects: H3. Reductions in experien- tial avoidance will mediate reductions in grief and posttraumatic stress. This study is expected to confirm EMPOWER's efficacy and enhance understanding of ways to improve telehealth delivery to psychologically vulnerable and historically underserved surrogates. If successful, EMPOWER will address the urgent need for effective, culturally competent interventions for distressed surrogates, which may improve critically ill patients' EoL experience in the context of extreme challenges that have been exacerbated by the COVID-19 pandemic.", "keywords": [ "Address", "Advance Care Planning", "Affect", "Anger", "Behavioral", "Bereavement", "Black race", "Black Indigenous People of Color", "Breathing", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "Caregivers", "Caring", "Cessation of life", "Cognitive", "Communication", "Confusion", "Conscious", "Coronavirus", "Critical Illness", "Data", "Decision Making", "Disease", "Disorientation", "Dissemination and Implementation", "Distress", "Emotional", "Equipment and supply inventories", "Family", "Family Caregiver", "Family health status", "Family member", "Feeling", "Goals", "Grief reaction", "Guilt", "Hospitals", "Indigenous", "Intensive Care Units", "Intervention", "Interview", "Left", "Life", "Life Experience", "Loneliness", "Mediating", "Mediation", "Mediator", "Medical", "Medical center", "Memorial Sloan-Kettering Cancer Center", "Mental Depression", "Mental Health", "Methods", "Modeling", "Numbness", "Outcome", "Pain", "Palliative Care", "Parents", "Patient Care", "Patients", "Persons", "Positioning Attribute", "Post-Traumatic Stress Disorders", "Presbyterian Church", "Psychological Techniques", "Psychological adjustment", "Quality of Care", "Race", "Randomized", "Randomized Controlled Trials", "Regrets", "Reporting", "Risk", "Role", "Severities", "Site", "Social Distance", "Standardization", "Structure", "Symptoms", "Techniques", "Thinking", "Trauma", "United States", "United States National Institutes of Health", "Videoconferencing", "comparative efficacy", "contextual factors", "cultural competence", "disease transmission", "efficacy evaluation", "end of life", "end of life care", "experience", "flexibility", "future implementation", "improved", "insight", "intervention effect", "loved ones", "meetings", "pandemic disease", "people of color", "perceived discrimination", "post intervention", "post-traumatic stress", "post-traumatic symptoms", "primary outcome", "psychologic", "psychological distress", "psychological outcomes", "psychological trauma", "psychosocial", "racial disparity", "recruit", "reduce symptoms", "resilience", "secondary outcome", "stress symptom", "symptomatic improvement", "telehealth", "traumatic stress", "treatment as usual" ], "approved": true } }, { "type": "Grant", "id": "11649", "attributes": { "award_id": "5R01AI163142-02", "title": "A multipronged investigation of SARS-CoV-2 genome packaging", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26420, "first_name": "MARY KATHERINE", "last_name": "Bradford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-16", "end_date": "2027-03-31", "award_amount": 625894, "principal_investigator": { "id": 7461, "first_name": "Andrea", "last_name": "Soranno", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic, caused by the virus SARS-CoV-2, represents an acute and ongoing threat to human life. A detailed molecular understanding of the viral life cycle is necessary to illuminate clinically accessible processes that can be targeted for therapeutic intervention. The Nucleocapsid (N) protein is a 420-residue multidomain protein with both folded and disordered regions that underlies genome packaging, an essential step in the virion lifecycle. N protein mediates cytosolic genome packaging by binding to and compacting genomic RNA in a process apparently conserved across the coronaviridae family. Our ability to disrupt genome packaging is limited by the absence of a molecular understanding of these processes. To address this knowledge gap, our proposal is focused on the molecular biophysics that underlies how N protein drives genome compaction. N protein is highly multivalent; it can simultaneously bind to both itself and RNA via a number of distinct interaction sites. Multivalency is encoded across both folded domains and intrinsically disordered regions. While there has been substantial work on the folded domains in other coronaviruses, the molecular biophysics of the disordered regions has been largely ignored. We hypothesize N protein multivalency underlies the molecular basis of RNA compaction, and that the three disordered regions play key roles in determining multivalency, binding affinity, and RNA binding specificity. Through the combination of single-molecule fluorescence and force spectroscopy, ensemble methods, and all-atom simulation, we will dissect the molecular details that underlie these interactions. We also present a novel approach to small-molecule screening that leverages the formation of phase separated protein:RNA liquid droplets as a readout for genome compaction. Our work will offer high-resolution structural insight into the physical basis for two critical steps in the viral life cycle, as well as reveal small molecules that can attenuate genome compaction. More generally, by focusing on fundamental biophysical phenomena that empirically explain behavior from other distant coronaviruses, we believe that our conclusions will be broadly transferable to existing coronaviruses that represent major public health threats (e.g., SARS, MERS) but also to future novel zoonotic coronaviruses.", "keywords": [ "2019-nCoV", "Acute", "Address", "Affinity", "Antiviral Agents", "Attenuated", "Behavior", "Binding", "Biological Assay", "Biophysics", "COVID-19 pandemic", "Cells", "Clinical", "Coronavirus", "Coupled", "Data", "Development", "Diameter", "Disease", "Dissection", "Distant", "Encapsulated", "Family", "Fluorescence", "Fluorescence Spectroscopy", "Future", "Genome", "Goals", "Human", "In Vitro", "Investigation", "Knowledge", "Lead", "Length", "Life", "Life Cycle Stages", "Liquid substance", "Measurement", "Measures", "Mediating", "Methods", "Microscope", "Microscopy", "Middle East Respiratory Syndrome", "Molecular", "N Domain", "Nucleic Acids", "Nucleocapsid", "Phase", "Physical condensation", "Play", "Process", "Proteins", "Public Health", "Publishing", "RNA", "RNA Binding", "RNA Viruses", "RNA-Binding Proteins", "RNA-Protein Interaction", "Resolution", "Role", "SARS-CoV-2 genome", "Severe Acute Respiratory Syndrome", "Site", "Specificity", "Spectrum Analysis", "Tertiary Protein Structure", "Testing", "Therapeutic", "Therapeutic Intervention", "Vaccines", "Viral", "Viral Genome", "Viral Packaging", "Virion", "Virus", "Virus Replication", "Work", "betacoronavirus", "coronavirus therapeutics", "design", "experimental study", "genomic RNA", "high throughput screening", "insight", "novel", "novel strategies", "optic trap", "optical traps", "pandemic coronavirus", "prevent", "screening", "simulation", "single molecule", "small molecule", "targeted treatment", "zoonotic coronavirus" ], "approved": true } }, { "type": "Grant", "id": "5296", "attributes": { "award_id": "1R01AI163142-01A1", "title": "A multipronged investigation of SARS-CoV-2 genome packaging", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18631, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-16", "end_date": "2027-03-31", "award_amount": 631912, "principal_investigator": { "id": 18632, "first_name": "Andrea", "last_name": "Soranno", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic, caused by the virus SARS-CoV-2, represents an acute and ongoing threat to human life. A detailed molecular understanding of the viral life cycle is necessary to illuminate clinically accessible processes that can be targeted for therapeutic intervention. The Nucleocapsid (N) protein is a 420-residue multidomain protein with both folded and disordered regions that underlies genome packaging, an essential step in the virion lifecycle. N protein mediates cytosolic genome packaging by binding to and compacting genomic RNA in a process apparently conserved across the coronaviridae family. Our ability to disrupt genome packaging is limited by the absence of a molecular understanding of these processes. To address this knowledge gap, our proposal is focused on the molecular biophysics that underlies how N protein drives genome compaction. N protein is highly multivalent; it can simultaneously bind to both itself and RNA via a number of distinct interaction sites. Multivalency is encoded across both folded domains and intrinsically disordered regions. While there has been substantial work on the folded domains in other coronaviruses, the molecular biophysics of the disordered regions has been largely ignored. We hypothesize N protein multivalency underlies the molecular basis of RNA compaction, and that the three disordered regions play key roles in determining multivalency, binding affinity, and RNA binding specificity. Through the combination of single-molecule fluorescence and force spectroscopy, ensemble methods, and all-atom simulation, we will dissect the molecular details that underlie these interactions. We also present a novel approach to small-molecule screening that leverages the formation of phase separated protein:RNA liquid droplets as a readout for genome compaction. Our work will offer high-resolution structural insight into the physical basis for two critical steps in the viral life cycle, as well as reveal small molecules that can attenuate genome compaction. More generally, by focusing on fundamental biophysical phenomena that empirically explain behavior from other distant coronaviruses, we believe that our conclusions will be broadly transferable to existing coronaviruses that represent major public health threats (e.g., SARS, MERS) but also to future novel zoonotic coronaviruses.", "keywords": [ "2019-nCoV", "Acute", "Address", "Affinity", "Antiviral Agents", "Attenuated", "Behavior", "Binding", "Biological Assay", "Biophysics", "COVID-19 pandemic", "Caliber", "Cells", "Clinical", "Coronavirus", "Coupled", "Data", "Development", "Disease", "Dissection", "Distant", "Family", "Fluorescence", "Fluorescence Spectroscopy", "Future", "Genome", "Goals", "Human", "In Vitro", "Investigation", "Knowledge", "Lead", "Length", "Life", "Life Cycle Stages", "Liquid substance", "Measurement", "Measures", "Mediating", "Methods", "Microscope", "Microscopy", "Middle East Respiratory Syndrome", "Molecular", "Nucleic Acids", "Nucleocapsid", "Nucleocapsid Proteins", "Phase", "Physical condensation", "Play", "Process", "Proteins", "Public Health", "Publishing", "RNA", "RNA Binding", "RNA Viruses", "RNA-Binding Proteins", "RNA-Protein Interaction", "Resolution", "Role", "SARS-CoV-2 genome", "Severe Acute Respiratory Syndrome", "Site", "Specificity", "Spectrum Analysis", "Tertiary Protein Structure", "Testing", "Therapeutic", "Therapeutic Intervention", "Vaccines", "Viral", "Viral Genome", "Viral Packaging", "Virion", "Virus", "Virus Replication", "Work", "base", "betacoronavirus", "coronavirus therapeutics", "design", "experimental study", "genomic RNA", "high throughput screening", "insight", "novel", "novel strategies", "optical traps", "pandemic disease", "prevent", "screening", "simulation", "single molecule", "small molecule", "targeted treatment", "zoonotic coronavirus" ], "approved": true } }, { "type": "Grant", "id": "6416", "attributes": { "award_id": "3RF1AG053303-01S2", "title": "A Multipronged Interrogation of Large-Scale Omics Data to Reveal COVID-19 Pathways", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21572, "first_name": "Marilyn", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-09-15", "end_date": "2021-08-31", "award_amount": 650002, "principal_investigator": { "id": 21573, "first_name": "Sharlee", "last_name": "Climer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 21574, "first_name": "Carlos", "last_name": "Cruchaga", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 global pandemic has led to more than 470,000 deaths. This disease is especially perilous for the elderly - 80% of deaths in the US have been individuals over the age of 65, and the social isolation created by lockdowns have increased risks of serious physical and mental health issues. COVID-19 is a heterogeneous disease exhibiting a broad spectrum of symptoms, ranging from mild (e.g. loss of smell, dry cough) to critical (e.g. cytokine storm, renal failure, cardiovascular damage, respiratory failure, lethal blood clotting, neurological disorders). This clinical heterogeneity demands a precision medicine approach that elucidates distinct pathways underlying the disease, develops treatments for each pathway, and defines biomarker patterns to diagnose patients for classification within the subsets. A key benefit of precision medicine is that drugs may be repurposed or may already exist to treat specific subsets of infected individuals. For example, one critical outcome for COVID-19 infection is the onset of a cytokine storm, in which the body's immune system gets caught in a positive feedback loop, leading to shock and rapid failure of multiple organs. There are existing drugs for treating cytokine storm syndrome, but practitioners have no clear guidelines if such treatments are beneficial or destructive. If the individual is not in a hyperinflammatory state, the administration of these drugs could cripple their immune response, leading to increased viral load. Plasma biomarker patterns of proteins and metabolites hold potential to identify impending cytokine storms and other lethal outcomes. To advance precision medicine for COVID-19 treatment, this work will generate large-scale omics data and evaluate levels of proteins and metabolites for plasma drawn from 350 COVID-19 positive cases and 750 normal controls. These data will be immediately released to the research community. Our research team will take a concerted multipronged approach for analyzing these data using diverse complementary techniques. Our labs' research focuses on the discovery of combinations of genes and proteins expressing synchronously and the associations of these combinations with traits of interest, as well as endophenotype discovery. In addition to thorough single analyte analyses, this research will employ three computational strategies to reveal combinations of factors defining patterns: 1) network modeling, 2) explainable-AI systems biology, and 3) linear programming. These intensive analyses will require significant computational resources and we will utilize Summit at Oak Ridge National Laboratory, one of the most powerful supercomputers in the world, for these tasks. The comprehensive protein and metabolite profiles, based on a large cohort of COVID-19 cases and normal controls, along with our rigorous interrogation of these data for complex biomarker patterns indicative of patient outcomes, hold unprecedented potential to drive solid advances in precision medicine and to reduce mortality rates due to COVID-19. In addition, this research will provide an agile model for use when tackling other heterogeneous diseases plaguing humankind, as well as novel viruses that may arise in the future.", "keywords": [ "2019-nCoV", "Age", "Algorithms", "Anti-Inflammatory Agents", "Artificial Intelligence", "Biological", "Biological Markers", "Blood", "Blood coagulation", "COVID-19", "COVID-19 pandemic", "Cardiovascular system", "Cessation of life", "Characteristics", "Classification", "Clinical", "Clinical Sciences", "Communities", "Complex", "Consumption", "Coughing", "Data", "Data Analyses", "Data Set", "Death Rate", "Development", "Diagnosis", "Disabled Persons", "Disease", "Disease Outcome", "Disease Progression", "Drug Targeting", "Ebola", "Effectiveness", "Elderly", "Exhibits", "Feedback", "Foundations", "Future", "Gene Combinations", "Gene Proteins", "Genetic", "Guidelines", "HIV", "High Performance Computing", "Hospitalization", "Immune response", "Immune system", "Individual", "Infection", "Institute of Medicine (U.S.)", "Kidney Failure", "Laboratories", "Limb structure", "Linear Programming", "Mental Health", "Metadata", "Methods", "Middle East Respiratory Syndrome", "Modeling", "Molecular", "Multiple Organ Failure", "Mutate", "Natural Selections", "Outcome", "Pathway interactions", "Patient-Focused Outcomes", "Patients", "Pattern", "Performance", "Pharmaceutical Preparations", "Phenotype", "Plasma", "Pneumonia", "Precision therapeutics", "Proteins", "Proteomics", "Records", "Research", "Resources", "Respiratory Failure", "Risk", "Sample Size", "Sampling", "Severe Acute Respiratory Syndrome", "Shock", "Smell Perception", "Social isolation", "Solid", "Symptoms", "Syndrome", "Systems Biology", "Techniques", "Testing", "Time", "Toes", "Translational Research", "Universities", "Variant", "Viral Load result", "Virus", "Washington", "Work", "base", "clinical heterogeneity", "cohort", "complex data", "computing resources", "coronavirus disease", "cytokine release syndrome", "design", "diverse data", "drug candidate", "drug development", "effective therapy", "endophenotype", "fighting", "human old age (65+)", "individualized medicine", "interest", "medical schools", "metabolomics", "mortality", "nervous system disorder", "network models", "new therapeutic target", "novel", "novel therapeutics", "novel virus", "pandemic disease", "physical conditioning", "precision drugs", "precision medicine", "protein metabolite", "receptor", "response", "statistics", "supercomputer", "symposium", "trait", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "9403", "attributes": { "award_id": "1R42DE030829-01", "title": "A multimodal platform for Oral screening of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6931, "first_name": "Orlando", "last_name": "Lopez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-12-21", "end_date": "2022-11-30", "award_amount": 255999, "principal_investigator": { "id": 25135, "first_name": "ROYA", "last_name": "KHOSRAVI-FAR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1829, "ror": "", "name": "INNOTECH LLC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1829, "ror": "", "name": "INNOTECH LLC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The development of a rapid and reliable sensor system from readily available oral specimens is crucial for the screening and management of SARS-CoV-2 infection. Other than tests that require laboratory-scale instrumentation, the development of rapid tests can play a timely role in the management of an outbreak. Current rapid tests often involve the antibodies in a lateral flow format to detect viral protein components and, depending on the implementation, can result in a relatively high degree of error. In partnership with MIT, InnoTech proposes the development of a multiplexed sensor platform based on nanomaterials capable of molecular binding and subsequent reporting. We will develop and commercialize a multiplexed sensor platform using nanomaterial reporters capable of rapid simultaneous detection of multiple components of viral particles in a field applicable electrochemical device. For our Phase I- Aim 1 we will focus on the development and optimization of synthetic biosensors for accurate detection of SARS-CoV-2 viral proteins and nucleic acid. Our milestone is the discovery and validation an array of molecular recognition biosensors against both protein and nucleic acid segments of SARS-CoV-2. We will complete this phase in 4 months. In Phase II-Aim 1, we will develop and validate the electrochemical detectors. We will utilize the synthetic biosensors identified and validated in Aim 1 to an electrochemical platform for the rapid detection of an active SARS-CoV-2 infection using multiple biomarkers of the infection. We will specifically employ commercially-available, disposable electrode platforms and existing potentiostats from Metrohm DropSens to streamline scale-up and commercialization. Our milestone, to be completed in year 1 of Phase II, is to have a multiplex biosensor chip and an alpha prototype with a multiplex biosensor chip and a potentiostat reader which we will benchmark for sensitivity and quantitative accuracy against existing COVID-19 diagnostics. In Phase II-Aim 2, we will validate the prototype chips and detectors with retrospective clinical specimens in preparation for EUA-FDA submission. We will determine the LOD, clinical performance, and cross-reactivity with other respiratory pathogens and normal flora. The milestone for this Aim is to document a multiplex of at least two proteins and two nucleic acid biosensors for SARS-CoV-2 that will provide a LOD of 5-20 viruses per microliter in an oral specimen and will be clinically validated with greater than 95% concordance with RT-PCR in 30 positive and 30 negative specimens.", "keywords": [ "2019-nCoV", "Antibodies", "Benchmarking", "Binding", "Biological Markers", "Biosensing Techniques", "Biosensor", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 screening", "COVID-19 surveillance", "Clinical", "Computer software", "Custom", "Data Reporting", "Data Set", "Detection", "Development", "Devices", "Disease Management", "Disease Outbreaks", "Electrodes", "Engineering", "Equipment", "FDA Emergency Use Authorization", "Funding", "Genes", "Gold", "Human Resources", "Infection", "Israel", "Laboratories", "Lateral", "Libraries", "Measures", "Medical center", "Molecular", "Monitor", "Noise", "Nucleic Acids", "Nucleocapsid", "Nucleocapsid Proteins", "Oligonucleotides", "Open Reading Frames", "Oral", "Performance", "Phase", "Play", "Polymers", "Preparation", "Proteins", "RNA Sequences", "Reader", "Reagent", "Reporter", "Reporting", "Reverse Transcriptase Polymerase Chain Reaction", "Role", "SARS-CoV-2 infection", "Saliva", "Sampling", "Signal Transduction", "Site", "Specimen", "Structural Protein", "System", "Technology", "Temperature", "Testing", "Time", "Training", "Validation", "Viral", "Viral Load result", "Viral Proteins", "Viral Structural Proteins", "Virus", "Wireless Technology", "antigen test", "aptamer", "base", "commercialization", "cost", "cross reactivity", "detection limit", "detection platform", "detector", "instrumentation", "macromolecule", "medical schools", "molecular array", "molecular recognition", "multimodality", "nanomaterials", "normal microbiota", "oral pathogen", "pandemic disease", "particle", "prototype", "rapid detection", "rapid test", "respiratory pathogen", "response", "scale up", "screening", "sensor", "single walled carbon nanotube" ], "approved": true } }, { "type": "Grant", "id": "10346", "attributes": { "award_id": "3R42DE030829-01S1", "title": "A multimodal platform for Oral screening of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6931, "first_name": "Orlando", "last_name": "Lopez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2022-11-30", "award_amount": 500000, "principal_investigator": { "id": 25135, "first_name": "ROYA", "last_name": "KHOSRAVI-FAR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1829, "ror": "", "name": "INNOTECH LLC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1829, "ror": "", "name": "INNOTECH LLC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Original Abstract A multimodal platform for Oral screening of COVID-19 The development of a rapid and reliable sensor system from readily available oral specimens is crucial for the screening and management of SARS-CoV-2 infection. Other than tests that require laboratory-scale instrumentation, the development of rapid tests can play a timely role in the management of an outbreak. Current rapid tests often involve the antibodies in a lateral flow format to detect viral protein components and, depending on the implementation, can result in a relatively high degree of error. In partnership with MIT, InnoTech proposes the development of a multiplexed sensor platform based on nanomaterials capable of molecular binding and subsequent reporting. We will develop and commercialize a multiplexed sensor platform using nanomaterial reporters capable of rapid simultaneous detection of multiple components of viral particles in a field applicable electrochemical device. For our Phase I- Aim 1 we will focus on the development and optimization of synthetic biosensors for accurate detection of SARS-CoV-2 viral proteins and nucleic acid. Our milestone is the discovery and validation an array of molecular recognition biosensors against both protein and nucleic acid segments of SARS-CoV-2. We will complete this phase in 4 months. In Phase II-Aim 1, we will develop and validate the electrochemical detectors. We will utilize the synthetic biosensors identified and validated in Aim 1 to an electrochemical platform for the rapid detection of an active SARS-CoV-2 infection using multiple biomarkers of the infection. We will specifically employ commercially-available, disposable electrode platforms and existing potentiostats from Metrohm DropSens to streamline scale-up and commercialization. Our milestone, to be completed in year 1 of Phase II, is to have a multiplex biosensor chip and an alpha prototype with a multiplex biosensor chip and a potentiostat reader which we will benchmark for sensitivity and quantitative accuracy against existing COVID-19 diagnostics. In Phase II-Aim 2, we will validate the prototype chips and detectors with retrospective clinical specimens in preparation for EUA-FDA submission. We will determine the LOD, clinical performance, and cross-reactivity with other respiratory pathogens and normal flora. The milestone for this Aim is to document a multiplex of at least two proteins and two nucleic acid biosensors for SARS- CoV-2 that will provide a LOD of 5-20 viruses per microliter in an oral specimen and will be clinically validated with greater than 95% concordance with RT-PCR in 30 positive and 30 negative specimens.", "keywords": [ "2019-nCoV", "Antibodies", "Antigens", "Automobile Driving", "Award", "Benchmarking", "Binding", "Biological Assay", "Biological Markers", "Biosensing Techniques", "Biosensor", "Businesses", "COVID diagnostic", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 screening", "Clinical", "Collection", "Communicable Diseases", "Computer software", "Detection", "Development", "Devices", "Diagnostic", "Diagnostic tests", "Disease", "Disease Outbreaks", "Electrodes", "Elements", "FDA Emergency Use Authorization", "Future", "Hour", "Housekeeping", "Human", "Individual", "Infection", "Infectious Agent", "Influenza", "Laboratories", "Lateral", "Microfluidic Microchips", "Microfluidics", "Molecular", "Nature", "Nucleic Acids", "Optics", "Oral", "Patient Care", "Patients", "Performance", "Phase", "Play", "Preparation", "Process", "Proteins", "Provider", "Public Health", "RADx Radical", "Reader", "Readiness", "Reporter", "Reporting", "Reproducibility", "Reverse Transcriptase Polymerase Chain Reaction", "Role", "Running", "SARS-CoV-2 B.1.617.2", "SARS-CoV-2 infection", "Saliva", "Sampling", "Screening Result", "Signal Transduction", "Site", "Small Business Technology Transfer Research", "Specimen", "System", "Technology", "Technology Transfer", "Testing", "Time", "Time Management", "United States National Institutes of Health", "Validation", "Viral", "Viral Proteins", "Virus", "Washington", "Work", "antibody detection", "base", "clinical application", "combat", "commercialization", "cost", "cross reactivity", "design", "design verification", "detection limit", "detector", "electrochemical device", "emerging pathogen", "experience", "innovation", "instrumentation", "manufacturability", "miniaturize", "molecular array", "molecular recognition", "multimodality", "nanomaterials", "nanosensors", "normal microbiota", "pandemic disease", "pandemic preparedness", "particle", "pathogen", "point of care", "portability", "precision medicine", "prototype", "rapid detection", "rapid test", "respiratory pathogen", "response", "sample collection", "scale up", "screening", "sensor", "transmission process", "treatment planning" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1424, "count": 14236 } } }